Tyme Technologies, Inc. (TYME): Price and Financial Metrics
GET POWR RATINGS... FREE!
TYME Stock Price Chart Interactive Chart >
TYME Price/Volume Stats
| Current price | $1.29 | 52-week high | $4.99 |
| Prev. close | $1.32 | 52-week low | $0.85 |
| Day low | $1.28 | Volume | 1,215,600 |
| Day high | $1.31 | Avg. volume | 7,457,445 |
| 50-day MA | $1.44 | Dividend yield | N/A |
| 200-day MA | $1.46 | Market Cap | 222.15M |
Tyme Technologies, Inc. (TYME) Company Bio
Tyme Technologies, Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology indications. It is developing SM-88, a combination therapy in Phase II development for prostate cancer. The company was founded in 2011 and is based in New York, New York.
Latest TYME News From Around the Web
Below are the latest news stories about Tyme Technologies Inc that investors may wish to consider to help them evaluate TYME as an investment opportunity.
Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Tyme Technologies, Inc. 2021 Q4 - Results - Earnings Call PresentationThe following slide deck was published by Tyme Technologies, Inc. in conjunction with their 2021 Q4 earnings call.... |
Tyme Technologies, Inc. Completes Strategic Review, Announces OASIS Breast Trial With Georgetown University, and Reports Fiscal Year 2021 Financial ResultsTyme Technologies, Inc. (Nasdaq:TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today reported its conclusions from its recently conducted comprehensive strategic review and its fourth quarter and fiscal year 2021 financial results. |
Tyme Technologies: Recent Sell-Off Provides Opportunity To Buy At A DiscountPhoto by peterschreiber.media/iStock via Getty Images Tyme Technologies (TYME) continues to be a below-par investment to date, yet, I still trust my "bamboo investment” approach will yield significant gains as the company begins to report pivotal trial readouts for their SM-88 product in pancreatic cancer. Furthermore, I believe the company’s... |
TYME Technologies, Inc. to Host Conference Call and Live Video Webcast on Thursday, June 10th at 5:00 PM ETTYME Technologies, Inc. (Nasdaq: TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTstm), today announced that it will host a conference call and live video webcast on Thursday, June 10, 2021 at 5:00 PM ET. The Company will report its fiscal year 2021 financial results and provide a business update that same day. |
TYME Price Returns
| 1-mo | -5.15% |
| 3-mo | -39.44% |
| 6-mo | 11.21% |
| 1-year | -4.80% |
| 3-year | -63.66% |
| 5-year | N/A |
| YTD | 5.74% |
| 2020 | -12.86% |
| 2019 | -62.06% |
| 2018 | -42.16% |
| 2017 | 70.13% |
| 2016 | N/A |
Loading social stream, please wait...